Genelux logo

Genelux

GNLX | NASDAQ
Chart Builder DCF Calculator
$1.92
+$0.05 (+2.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.80
-$0.12 (-6.16%)
After-hours: Nov 16, 2026, 7:20 PM ET
+2.95%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
34.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #659/1021 (Top 65%)

Key Statistics

Market Data

Market Cap $86.87M
1D Range
1.86 2.02
52W Range
1.82 5.59

Valuation (TTM)

PE -2.16
PB 5.39
EV/EBITDA -2.07

Valuation (NTM)

Forward PE N/A
Forward PEG 0.56
Price Target $16.00
Loading financial charts...

Profile

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor ma...

Sector Healthcare
Industry Biotechnology
Employees 26
IPO Date Jan 26, 2023
Fiscal Year January - December

Latest News

No news articles available yet.

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$16.00
Upside
+733.33%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.